Atención temprana y toxina botulínica. Nuestra experiencia en el siglo XXI / Early care and botulinum toxin our experience in the 21ST century
Rev. neurol. (Ed. impr.)
; Rev. neurol. (Ed. impr.);47(supl.1): 25-33, 2 sept., 2008. ilus
Article
en Es
| IBECS
| ID: ibc-69889
Biblioteca responsable:
ES15.1
Ubicación: ES15.1 - BNCS
Introducción. En neuropediatría, el diagnóstico etiológico pocas veces permite un tratamiento causal. En muchas ocasiones sólo podemos ofrecer la derivación a atención temprana (AT) y la toxina botulínica tipo A (TBA). Ambas intervenciones sólo precisan para su inicio el diagnóstico funcional o sindrómico. Pacientes y métodos. Se analiza la experiencia enel programa de AT para Aragón desde febrero de 2003 y con la consulta de TBA de la Unidad de Neuropediatría del Hospital Universitario Miguel Servet desde noviembre de 2003. Resultados. El número de solicitudes al programa de AT hasta finales de 2007 ascendía a 2.629, y en 2007 se atendía a 702 niños. En cuatro años y cuatro meses se ha infiltrado con TBA a 122 niñoscon parálisis cerebral infantil, con resultados positivos del 70%, y efectos adversos leves y transitorios del 13,1%. Conclusiones. La AT y la TBA se perciben con alta satisfacción por niños, padres y profesionales implicados. La neuropediatría es una de las especialidades médicas más adecuadas en los equipos de atención temprana (CDIAT). El neuropediatra participaen todas las etapas de AT: detección, diagnóstico, información e intervención. Puede ser el elemento coordinador y homogeneizador de la AT, el enlace entre CDIAT y servicios sanitarios. Es necesario en programas de formación y docencia de AT, en campañas de sensibilización, información y formación de familias, atención primaria, servicios sociales y guarderías.El tratamiento con TBA no puede entenderse como una técnica aislada, sino dentro de un programa donde son fundamentales fisioterapia, ortesis y, en ocasiones, cirugía. Es imprescindible la coordinación con los profesionales implicados en el tratamientodel niño con parálisis cerebral infantil
Introduction. In neuropaediatrics, the aetiological diagnosis rarely allows a causal treatment to be established. In many cases, all we can offer is referral to early intervention (EI) and botulinum toxin type A (BTA). The only requirement before starting both interventions is a functional or syndromic diagnosis. Patients and methods. Here we analyse the experience gained from an EI programme carried out in the region of Aragon since February 2003 and with the BTA servicein the Neuropaediatric Unit of the Hospital Universitario Miguel Servet since November 2003. Results. By the end of 2007, 2629 requests had been made for admission to the EI programme and in the year 2007 a total of 702 children were treated. Infour years and four months 122 children with infantile cerebral palsy (ICP) were infiltrated with BTA, with positive results in 70% of cases and mild, transient side effects in 13.1%. Conclusions. The children, parents and professionals involved all view EI and BTA with satisfaction. Neuropaediatrics is one of the medical specialties that are best suited to child development andearly intervention centres (CDIAT). The neuropaedia-trician participates in all the stages of the EI: detection, diagnosis, information and intervention. He or she may act as the coordinating and homogenising element in EI, that is to say, as a link between CDIAT and health care services. Neuropaediatricians are also essential in EI training and education, in familytraining, information and awareness campaigns, primary care, social services and nurseries. Treatment with BTA cannot be viewed as an isolated technique, but instead as part of a programme in which physiotherapy, orthosis and sometimes surgery play a fundamental role. Coordination among the different professionals involved in treating the child with ICP is absolutelycrucial
Introduction. In neuropaediatrics, the aetiological diagnosis rarely allows a causal treatment to be established. In many cases, all we can offer is referral to early intervention (EI) and botulinum toxin type A (BTA). The only requirement before starting both interventions is a functional or syndromic diagnosis. Patients and methods. Here we analyse the experience gained from an EI programme carried out in the region of Aragon since February 2003 and with the BTA servicein the Neuropaediatric Unit of the Hospital Universitario Miguel Servet since November 2003. Results. By the end of 2007, 2629 requests had been made for admission to the EI programme and in the year 2007 a total of 702 children were treated. Infour years and four months 122 children with infantile cerebral palsy (ICP) were infiltrated with BTA, with positive results in 70% of cases and mild, transient side effects in 13.1%. Conclusions. The children, parents and professionals involved all view EI and BTA with satisfaction. Neuropaediatrics is one of the medical specialties that are best suited to child development andearly intervention centres (CDIAT). The neuropaedia-trician participates in all the stages of the EI: detection, diagnosis, information and intervention. He or she may act as the coordinating and homogenising element in EI, that is to say, as a link between CDIAT and health care services. Neuropaediatricians are also essential in EI training and education, in familytraining, information and awareness campaigns, primary care, social services and nurseries. Treatment with BTA cannot be viewed as an isolated technique, but instead as part of a programme in which physiotherapy, orthosis and sometimes surgery play a fundamental role. Coordination among the different professionals involved in treating the child with ICP is absolutelycrucial
Buscar en Google
Colección:
06-national
/
ES
Base de datos:
IBECS
Asunto principal:
Parálisis Cerebral
/
Toxinas Botulínicas Tipo A
Tipo de estudio:
Diagnostic_studies
/
Screening_studies
Límite:
Female
/
Humans
/
Male
/
Newborn
Idioma:
Es
Revista:
Rev. neurol. (Ed. impr.)
Año:
2008
Tipo del documento:
Article